PharmaCyte Biotech, Inc.
NASDAQ Capital MarketTotal Valuation
PharmaCyte Biotech, Inc. carries a market capitalization of 4.15M, placing it among publicly traded companies globally. Its enterprise value stands at -13.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.15M |
| Enterprise Value | -13.43M |
Share Statistics
PharmaCyte Biotech, Inc. currently has 10.74M shares outstanding.
| Shares Outstanding | 10.74M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
PharmaCyte Biotech, Inc. trades at a trailing price-to-earnings ratio of 0.24.
| PE Ratio | 0.24 |
| PS Ratio | N/A |
| PB Ratio | -0.06 |
| P/TBV Ratio | 0.17 |
| P/FCF Ratio | -1.30 |
| P/OCF Ratio | -1.30 |
Financial Position
PharmaCyte Biotech, Inc. maintains a current ratio of 12.33, meaning it holds 12.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.33 |
| Quick Ratio | 12.24 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -6.58 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -29.14 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
PharmaCyte Biotech, Inc.'s stock has declined approximately -38.33637% over the past 52 weeks. The 50-day moving average sits at 0.75, while the 200-day moving average is 0.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | -38.33637% |
| 50-Day Moving Average | 0.75 |
| 200-Day Moving Average | 0.80 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -5.38M, while operating income came in at -5.38M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -5.38M |
| Pretax Income | -3.28M |
| Net Income | -3.28M |
| EBITDA | -5.38M |
| EBIT | -5.38M |
| Earnings Per Share (EPS) | -0.43 |
Balance Sheet
Total book value stands at -100.00M, with working capital of 19.02M providing operational flexibility.
| Cash & Cash Equivalents | 20.54M |
| Total Debt | N/A |
| Net Debt | -20.17M |
| Equity (Book Value) | -100.00M |
| Book Value Per Share | -13.13 |
| Working Capital | 19.02M |
Cash Flow
PharmaCyte Biotech, Inc. produced -4.80M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.80M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.80M |
| FCF Per Share | -0.63 |
Dividends & Yields
The company's payout ratio of 5.61 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 5.61 |
| Shareholder Yield | -105.46 |
| FCF Yield | -76.94 |
Stock Splits
PharmaCyte Biotech, Inc.'s most recent stock split took place on July 12, 2021 with a 1550:1 split ratio.
| Last Split Date | 7/12/2021 |
| Split Ratio | 1550:1 |
Scores
PharmaCyte Biotech, Inc. posts an Altman Z-Score of -2.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.26 |